DLBCL Germinal Center B-Cell Type

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Antengene
AntengeneChina - Shanghai
1 program
1
SelinexorPhase 21 trial
Active Trials
NCT05422066RecruitingEst. Dec 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
AntengeneSelinexor

Clinical Trials (1)

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Start: Jul 2022Est. completion: Dec 2025
Phase 2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space